Рак предстательной железы и качество жизни

1. Fayers P.M., Jones D.R. Measuring and analyzing quality of life in cancer clinical trials: a review. Stat Med 1983;2(4):429–46.

2. Patrick D.L., Erickson P. Assessing health-related quality of life for clinical decision-making. Kluwer Academic Publisher, Dordrecht; 1993.

3. Gill T.M., Feinstein A.R. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994;272(8):619–26.

4. Новик А.А. Концепция исследования качества жизни в медицине. Санкт-Петербург, ЭЛБИ; 1999.

5. WHOQOL Group, Division of Mental Heals, World Health Organization. Study protocol for the World Health Organization: organization to develop a Quality of Life assessment instrument (WHOQOL). J Qual Life Res 1993;2(2): 153–9.

6. Stewart A.L., Hays R.D., Ware J.E. The MOS SF-36 shot-form general health survey. Reliability and validity in patient population. Med Care 1988;26(7):724–35.

7. Cella D.F., Tulsky D.S. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Invest 1993;11(3):327–36.

8. Jenial A., Tiwari R.C., Murray T. et al. Cancer statistics. CA Cancer J Clin 2004;54(l):8–29.

9. Giyar G.H., Feeny D.K., Patrick D.L. Measuring health-related quality of life. Ann Intern Med 1993;118(8):622–9.

10. Щепия О.П. Здоровье населения Российской Федерации: проблемы и перспективы. Вестн РАМН 1996;(6):11–5.

11. Aaronson N.K. Quality of life assessment in clinical trials: methodologic issues. Control Clin Trials 1980;10:195–208.

12. Bowling A. Measuring disease. A review of disease-specific quality of life measurement scales. Philadelphia, Open University Press; 1996.

13. Tulsky D.S. An introduction to test theory. Oncology 1990;4(5):43–8.

14. Patrick D.L., Deyo R.A. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27(3 Suppl):S217–32.

15. Bergner M., Bobbitt К.A., Carter W.B. et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19(8):787–805.

16. Moinpour C.M., Feigl P., Metch B. et al. Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst 1989;81(7):485–95.

17. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473–83.

18. Kaplan R.M., Ganiats T.G., Sieber W.J. et al. The quality of well-being scale: critical similarities and differences with SF-36. Int J Qual Health Care 1998;10(6):509–20.

19. Сухонос Ю. А. Особенности популяционного исследования качества жизни. Автореф. дис… канд. мед. наук. С.Пб., 2003.

20. Aaronson N.К., Ahmedzai S., Bergman В. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85(5):365–76.

21. Cella D.F., Tulsky D.S. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;ll(3): 570–9.

22. Schag C.A., Heinrich R.L. Development of a comprehensive quality of life measurement tool: CARES. Oncology 1990;4(5):135–8.

23. De Haes J.C., van Knippenberg F.C., Neijt J.P. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990;62(6):1034–8.

24. Litwin M.S., Hays R.D., Fink A. et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a healthrelated quality of life measure. Med Care 1998;36(7):1002–12.

25. Esper P., Mo F., Chorale G. et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997;50(6):920–8.

26. Da Silva F.С., Fossa S.D., Aaronson N.K. et al. The quality of life of patients with newly diagnosed Ml prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer 1996;32A(1):72–7.

27. Augustin H., Pummer К., Daghofer F. et al. Patient self-reporting questionnaire on urological morbidity and bother after radical retropubic prostatectomy. Eur Urol 2002;42(2):112–7.

28. Wei J.Т., Dunn R.L., Litwin M.S. et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56(6):899–905.

29. Aus G., Abbou C.C., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2005;48(4):546–51.

30. Litwin M.S., Hays R.D., Fink A. et al. Quality-of-life outcomes in men treated for localised prostate cancer. JAMA 1995;273(2):129–35.

31. Joly F., Brune D., Couette J.E. et al. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol 1998;9(7):751–7.

32. Arredondo S.A., Downs T.M., Lubeck D.P. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol 2004;172(5):1830–4.

33. Madalinska J.В., Essink-Bot M.-L., de Koning H.J. et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001;19(6):1619–28.

34. Steineck G., Helgesen F., Adolfsson J. et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347(11):790–6.

35. Johnson T.K., Gilliland F.D., Hoffman R.M. et al. Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol 2004;22(20):4193–201.

36. Петров С.Б., Ракул С.А. Качество жизни пациентов после позадилонной радикальной простатэктомии. Урология 2006;(1):25–8.

37. Potosky A., Legler J., Albertsen P. et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer. J Natl Cancer Inst 2000;92(19):1582–92.

38. Stanford J.L., Feng Z., Hamilton A.S. et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The prostate cancer outcomes study. JAMA 2000;283(3):354–60.

39. Wei J.Т., Dunn R.L., Sandler H.M. et at. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002;20(2):557–66.

40. Merrick G.S., Butier W.M., Dorsey A.T. et al. Rectal function following prostate brachytherapy. Int J Radiat Oncoi Biol Phys 2000;48(3):667–74.

41. Davis J.W., Kuban D.A., Lynch D.F., Schellhammer P.F. Quality of life after treatrnent for localized prostate cancer: differences based on treatment modality. J Uroi 2001;166(3):947–63.

42. Litwin M.S., Sadetsky N., Pasta D.J., Lubeck D.P. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol 2004;172(2):515–9.

43. Helgason A.R., Adolfsson J., Dickman P. et al. Factors associated with waning sexual function among elderly men and prostate cancer patients. J Urol 1997;158(1):155–9.

44. Mants С.A., Nautiyal J., Awan A. et al. Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique and patient-related factors. Cancer J Sci Am 1999;5(4):230–6.

45. Penson D.F., Feng Z., Kuniyuki A. et al. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? results from the prostate cancel outcomes study. J Clin Oncol 2003;21(6):1147–54.

46. Clark J.A., Rieker P., Propert K.J. et al. Changes in quality of life following treatment for early prostate cancer. Urology 1999;53(1):161–8.

47. Litwin M.S., McGuigan K.A., Shpall A.I., Dhanani N. Recovery of health related quality of life in the year after radical prostatectomy: early experience. J Urol 1999;161(2):515–9.

48. Noldus J., Michl U., Graefen M. et al. Patient-reported sexual function after nerve-sparing radical retropubic prostatectomy. Eur Urol 2002;42(1):118–24.

49. Link R.E., Su L.-M., Sullivan W. et al. Health related quality of life before and after laparoscopic radical prostatectomy. J Urol 2005;173(1):175–9.

50. Zabora J., Brintzenhofeszoc K., Cubow B. et al. The prevalence of psychological distress by cancer site. Psychooncology 2001;10(1):19–28.

51. Trask P.C. Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy. Health Qual Life Outcomes 2004;2:37–41.

52. Litwin M.S., Flanders S.C., Pasta D.J. et al. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999;54(3):503–8.

53. Green H.J., Pakenham K.I., Headley B.C., Gardiner R.A. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology 2002;11(5):401–14.

54. Dacal K., Sereika S.M., Greenspan S.L. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 2006;54(1):85–90.

55. Chodak G., Sharifi R., Kasimis B. et al. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995;46(6):849–55.

56. Boccardo F., Rubagotti A., Barichello M. et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17(7):2027–38.

57. Litwin M. S.,Shpall A.I., Dorey F., Nguyen T.H. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 1998;21(4):327–32.

58. Curran D., Fossa S., Aaronson N. Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG). Eur J Cancer 1997;33(11):1809–14.

59. Melmed G.Y., Kwan L., Reid K. Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology 2002;59(1):103–9.

60. Jonler M., Nielsen O.S., Groenvold M. et al. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5. Scand J Urol Nephrol 2005;39(1):42–8.

61. Osoba D., Tannock I.F., Ernst D.S., Neville A.J. Health-related quality of life in men with metstatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17(6):1654–63.

62. Autorino R., Di Lorenzo G., Damiano R. et al. Role of chemotherapy in hormone-refractory prostate cancer: Old issues, recent advances and new perspectives. Urol Int 2003;70(1):1–14.

63. Sinibaldi V.J., Carducci M., Laufer M., Eisenberger M. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin Oncol 1999;26(1):45–8.

64. Copur M.S., Ledakis P., Lynch J. et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 2001;28(4, Suppl 15):16–21.

65. Kornblith A.B., Herndon J.E. 2nd, Zuckerman E. et al. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study. Ann Oncol 2001;12(5)633–41.